Evidence map›Paper›PMID 32740063›Full record

ReviewCurrent opinion in ophthalmology2020

Ebola, COVID-19, and emerging infectious disease: lessons learned and future preparedness.

J Clay Bavinger, Jessica G Shantha, Steven Yeh

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Economic Burden of COVID-19 Hospitalization in Almaty, Kazakhstan.ClinicoEconomics and outcomes research : CEOR · 2026
    Article
  3. Article
  4. Promising Vaccine Formulations for Emerging Infectious Diseases.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

J Clay BavingerDepartment of Ophthalmology, Emory University, Atlanta, Georgia, USA.
Jessica G Shantha
Steven Yeh
Emory University · USEmory Eye Center · US

Funding

P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI GROSSNIKLAUS, HANS E. · 1986 to 2025
$15.3M
Pathogenesis of Uveitis in Ebola Virus Disease SurvivorsR01EY029594 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI YEH, STEVEN · 2019 to 2023
$2.9M
Ophthalmic Disease and Laboratory Surveillance in a Viral Hemorrhagic Fever ZoneK23EY030158 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANTHA, JESSICA · 2019 to 2023
$1.2M
NEI NIH HHS K23 EY030158NEI NIH HHS L30 EY029526NEI NIH HHS P30 EY006360NEI NIH HHS R01 EY029594
6 · The paper itself

Abstract

purpose of reviewTo highlight the lessons learned from the Ebola outbreak that may inform our approach to the COVID-19 pandemic, particularly related to the widespread disruption of healthcare, ophthalmic disease manifestations, and vision health systems strengthening for future outbreaks. RECENT

findingsCoronavirus disease 2019 (COVID-19), first detected in China in December 2019, has become a worldwide health emergency, with significant disruption of all aspects of society, including travel, business, and medical care. Although this pandemic has had unprecedented effects on healthcare delivery in the United States, experiences from recent Ebola virus disease (EVD) outbreaks in Africa provide insight and inform our approach to COVID-19 and outbreak preparedness. Like COVID-19, the rapid emergence of Ebola required new clinical and surgical approaches to understand its associated spectrum of ophthalmic complications and the potential for Ebola viral persistence within the eye and in tear film. Recent reports of ophthalmic findings associated with COVID-19 include conjunctivitis, retinopathy, and molecular evidence of virus within the tear film in a minority of cases. Yet, more rigorous approaches to understand ophthalmic disease and transmission risk associated with COVID-19 are needed. Gaps also remain in our understanding of eye disease associated with other high priority emerging infectious diseases including Nipah, Lassa fever, Marburg virus, and others. SUMMARY: Thoroughly understanding the ophthalmic findings and transmission risk associated with COVID-19 is paramount during this pandemic, providing additional measures of safety while resuming ophthalmic care for all patients. Vision health systems preparedness measures developed during recent EVD outbreaks and the current pandemic provide models for ophthalmic clinical practice, research, and education, as we continue to address COVID-19 and future emerging infectious disease threats.

Indexed as

BetacoronavirusDisease OutbreaksCivil DefenseCommunicable Diseases, EmergingCoronavirus InfectionsCOVID-19Delivery of Health CareDisease Transmission, InfectiousGlobal HealthHemorrhagic Fever, EbolaHumansPandemicsPneumonia, ViralSARS-CoV-2

Identifiers

PMID32740063
PMCPMC7755289
OpenAlexW3046730516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.